Journal
ENDOCRINOLOGY
Volume 148, Issue 3, Pages 936-941Publisher
ENDOCRINE SOC
DOI: 10.1210/en.2006-0921
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA088041] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA 88041] Funding Source: Medline
Ask authors/readers for more resources
Thyroid papillary carcinoma is the most common type of endocrine cancer. It is frequently associated with genetic alterations leading to activation of the MAPK signaling pathway. The two most frequently affected genes, BRAF and RET, are activated by either point mutation or as a result of chromosomal rearrangement. These mutations are tumorigenic in thyroid follicular cells and correlate with specific phonotypical features and biological properties of papillary carcinomas, including tumor aggressiveness and response to radioiodine therapy. Molecular inhibitors that block RET/PTC or BRAF kinase activity have shown substantial therapeutic effects in the experimental systems and are currently being tested in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available